An Open Label, 2-Period, Sequential Study to Determine the Impact of Multiple Doses of Rifampin on Single-Dose Pharmacokinetics of HCV-796 [nesbuvir]

Trial Profile

An Open Label, 2-Period, Sequential Study to Determine the Impact of Multiple Doses of Rifampin on Single-Dose Pharmacokinetics of HCV-796 [nesbuvir]

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2009

At a glance

  • Drugs Nesbuvir (Primary) ; Rifampicin
  • Indications Bacterial infections; Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 18 Aug 2009 Planned end date changed from 1 Oct 2006 to 1 Nov 2006 as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Apr 2008 Development of nesbuvir has been discontinued due to safety issues, according to a ViroPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top